STATE OF NEW YORK

9360

2025-2026 Regular Sessions

IN ASSEMBLY

December 19, 2025

Introduced by M. of A. SANTABARBARA -- read once and referred to the Committee on Health

AN ACT to amend the social services law, in relation to requiring Medicaid coverage of FDA-approved GLP-1 receptor agonist medications for obesity, metabolic disorders, and autism-related compulsive eating behaviors

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subdivision 2 of section 365-a of the social services law is amended by adding a new paragraph (oo) to read as follows:

(oo) (i) Federal food and drug administration approved GLP-1 receptor agonist medications for the following medically indicated purposes:

(1) obesity treatment in individuals with a body mass index of thirty or greater, or individuals with a body mass index of twenty-seven or greater with a related comorbidity;

(2) metabolic disorders, including prediabetes, type two diabetes and metabolic syndrome; and

(3) clinically verified autism-related compulsive eating behaviors with certification from a qualified clinician, which shall include a developmental pediatrician, neurologist, psychiatrist, psychologist, or other licensed provider.

(ii) The department of health is authorized to require the following:

(1) step therapy protocols for such medications, where clinically appropriate;

(2) prior authorization of such medications to ensure medical necessity of such medications;

(3) income-based eligibility prioritization for high-need, low-income Medicaid recipients to receive coverage for such medications; and/or

(4) documentation requirements for clinician certification in cases of autism-related need for such medications pursuant to clause three of subparagraph (i) of this paragraph.

EXPLANATION--Matter in *italics* (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD14216-01-5

(iii) The department of health shall:

(1) develop clear rules and clinical criteria for coverage of GLP-1 receptor agonist medications within one hundred eighty days of the effective date of this paragraph;

(2) streamline prior authorization forms and timelines;

(3) evaluate health outcomes and potential Medicaid cost savings related to the coverage of such medications; and

(4) submit an annual report to the legislature detailing utilization, costs and measurable health outcomes related to the coverage of such medications.

(iv) The provisions of this paragraph shall apply to GLP-1 receptor agonist medications approved by the federal food and drug administration on or before the effective date of this paragraph, and shall also apply to emerging GLP-1 receptor agonist medications as such medications are approved by the federal food and drug administration after the effective date of this paragraph.

§ 2. This act shall take effect immediately.